{"id":30854,"date":"2025-11-11T13:07:57","date_gmt":"2025-11-11T21:07:57","guid":{"rendered":"https:\/\/getheally.com\/patients\/news\/why-some-patients-still-feel-hungry-on-glp-1-therapy-copy"},"modified":"2025-11-13T15:18:00","modified_gmt":"2025-11-13T23:18:00","slug":"how-to-set-realistic-goals-for-weight-loss-with-glp-1-treatments","status":"publish","type":"post","link":"https:\/\/getheally.com\/patients\/news\/how-to-set-realistic-goals-for-weight-loss-with-glp-1-treatments","title":{"rendered":"How to Set Realistic Goals for Weight Loss with GLP-1 Treatments"},"content":{"rendered":"

GLP-1 medications such as semaglutide<\/a> (Wegovy<\/a>, Ozempic<\/a>) and tirzepatide<\/a> (Zepbound<\/a>, Mounjaro<\/a>) \u00a0have transformed the landscape of weight management. These medications can significantly improve metabolic health and help users achieve sustained fat loss \u2014 but results vary from person to person. Setting realistic and achievable goals is key to ensuring long-term success and avoiding discouragement during your GLP-1 weight loss journey.<\/p>\n

Below, we\u2019ll walk through how to set meaningful goals, track progress, and stay motivated throughout your GLP-1 journey.<\/p>\n

Active Ingredient: Semaglutide<\/h4>\n

The active ingredient, Semaglutide, is a GLP-1 receptor agonist only. It mimics the hormone GLP-1, which helps regulate blood sugar and appetite<\/a>.<\/p>\n

\n
\n\n\n\n\n\n\n\n
Brand Name<\/th>\nManufacturer<\/th>\nRoute<\/th>\nFDA-Approved Use<\/th>\nFDA Approval Year<\/th>\n<\/tr>\n<\/thead>\n
Ozempic<\/a><\/td>\nNovo Nordisk<\/td>\nInjectable (weekly)<\/td>\nType 2 diabetes; Cardiovascular risk reduction<\/td>\n2017<\/td>\n<\/tr>\n
Wegovy<\/a><\/td>\nNovo Nordisk<\/td>\nInjectable (weekly)<\/td>\nChronic weight management<\/td>\n2021<\/td>\n<\/tr>\n
Rybelsus<\/a><\/td>\nNovo Nordisk<\/td>\nOral (daily tablet)<\/td>\nType 2 diabetes<\/td>\n2019<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
Throughout this article, any reference to semaglutide for weight loss refers to Wegovy. Mentions of semaglutide for blood sugar control refer to Ozempic.<\/div>\n<\/div>\n<\/div>\n

Active Ingredient: Tirzepatide<\/h4>\n

The active ingredient, Tirzepatide, is a dual agonist \u2014 it activates GLP-1 receptors and<\/em> GIP (glucose-dependent insulinotropic polypeptide) receptors. The added GIP activity<\/a> may enhance weight loss and blood sugar control compared to GLP-1\u2013only drugs.<\/p>\n

\n
\n\n\n\n\n\n\n
Brand Name<\/th>\nManufacturer<\/th>\nRoute<\/th>\nFDA-Approved Use<\/th>\nFDA Approval Year<\/th>\n<\/tr>\n<\/thead>\n
Mounjaro<\/a><\/td>\nEli Lilly<\/td>\nInjectable (weekly)<\/td>\nType 2 diabetes<\/td>\n2022<\/td>\n<\/tr>\n
Zepbound<\/a><\/td>\nEli Lilly<\/td>\nInjectable (weekly)<\/td>\nChronic weight management<\/td>\n2023<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
Throughout this article, any reference to Tirzepatide for weight loss refers to Zepbound. Mentions of Tirzepatide for blood sugar control refer to Mounjaro.<\/div>\n<\/div>\n<\/div>\n

Setting Realistic Weight Loss Goals with GLP-1 Medications<\/h2>\n

A realistic weight loss goal considers your starting weight, health conditions, metabolism, and lifestyle habits.<\/p>\n

While GLP-1s are highly effective, early results often differ from long-term averages. On average, most patients can expect<\/a>:<\/p>\n